flucloxacillin
Small moleculeexperimental
Flucloxacillin, also known as floxacillin, is an antibiotic used to treat skin infections, external ear infections, infections of leg ulcers, diabetic foot infections, and infection of bone. It may be used together with other medications to treat pneumonia, and endocarditis. It may also be used prior to surgery to prevent Staphylococcus infections. It is not effective against methicillin-resistant Staphylococcus aureus (MRSA). It is taken by mouth or given by injection into a vein or muscle. — Wikipedia
Clinical trial activity
15 trials · 26 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
5
Phase 3
3
Phase 4
4
Earliest trial started Jan 1, 2002 (NCT00405158)
Timeline
Indications
Approved for
Studied for
- Abscess · Phase 4
- Bacterial Infections · Phase 1
- Cellulitis · Phase 4
- Drug Interactions · Phase 1
- Erysipelas · Phase 4
- Healthy Volunteers · Phase 1
- Infections · Phase 2
- Osteomyelitis · Phase 2
- Renal Insufficiency, Chronic · Phase 1
- Skin Diseases, Bacterial · Phase 3
- Skin Diseases, Infectious · Phase 3
- Staphylococcal Infections · Phase 3
- Staphylococcus aureus · Phase 4
- Wound Infection · Phase 4
Mechanism of action
- Penicillin-binding protein 2DISRUPTING AGENT
Q53729 disrupting agent
- Bacterial penicillin-binding proteinINHIBITOR
Bacterial penicillin-binding protein inhibitor
- D-alanyl-D-alanine carboxypeptidase DacB (dacB) ↗
- Peptidoglycan D,D-transpeptidase FtsI (ftsI) ↗
- Penicillin-binding protein 1A (mrcA) ↗
- Penicillin-binding protein 1B (mrcB) ↗
- D-alanyl-D-alanine carboxypeptidase DacA (dacA) ↗
- Peptidoglycan D,D-transpeptidase MrdA (mrdA) ↗
- D-alanyl-D-alanine carboxypeptidase DacC (dacC) ↗
Chemistry & pharmacology
Loading structure…
SMILES
Cc1onc(-c2c(F)cccc2Cl)c1C(=O)N[C@@H]1C(=O)N2[C@@H]1SC(C)(C)[C@@H]2C(=O)O- Mol. weight
- 453.88 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFlucloxacillin ↗
- ChEMBLCHEMBL222645 ↗
Also known as
- (2s,5r,6r)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- (2s,5r,6r)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
- 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin
- 3-(2-chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin
- abboflox
- brl-2039
- brl-2039
- floxacillin
- floxacillin
- floxacillin
- floxacillin
- floxacillin
- floxacillin
- floxacillin
- floxapen
- floxapen
- fluclomix-250
- fluclomix-500
- flucloxacilina
- flucloxacilina
- flucloxacillin
- flucloxacillin
- flucloxacillin
- flucloxacillin
- flucloxacillin
- flucloxacillin
- flucloxacilline
- flucloxacilline
- flucloxacillin sodium
- flucloxacillin sodium
- flucloxacillin sodium
- flucloxacillinum
- flucloxacillinum
- flucloxin
- fluocloxacilin
- fluoxacillin
- galfloxin
- ladropen
- ladropen
- rimaflox
- stafoxil
- stafoxil
- staphlipen
- zoxin 250
- zoxin 500
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05584007 | Phase 3 | Mar 1, 2023 | Moorgreen Hospital, Southampton, University of East Anglia, University of Nottingham |
| NCT05655091 | Phase 2 | Feb 28, 2023 | University of Basel |
| NCT04840641 | Phase 1 | Mar 25, 2021 | SignaTope GmbH, Germany, University of Southern Denmark |
| NCT06454643 | N/A | Jan 1, 2020 | University of Baghdad |
| NCT03632642 | Phase 4 | Sep 30, 2018 | University of Queensland |
| NCT02922686 | Phase 4 | Dec 1, 2016 | Health Research Board, Ireland, Mater Misericordiae University Hospital, Mercy University, National University of Ireland, Royal College of Surgeons, Ireland |
| NCT02276482 | Phase 3 | Mar 25, 2015 | Cubist, Merck |
| NCT02334124 | N/A | Jan 1, 2015 | Murdoch University, University of Melbourne |
| NCT02032654 | Phase 4 | Aug 1, 2014 | University of Amsterdam, ZonMw: The Netherlands Organisation for Health Research and Development |
| NCT01792804 | Phase 3 | Dec 1, 2013 | German Research Foundation, University of Duesseldorf |
| NCT01876628 | Phase 4 | Oct 1, 2013 | Public Health England, University of Bristol |
| NCT00428844 | Phase 2 | Jan 1, 2007 | Cubist |
| NCT00433342 | Phase 1 | Mar 1, 2006 | Katholieke Universiteit Leuven |
| NCT00358371 | Phase 1 | Jan 1, 2005 | GlaxoSmithKline |
| NCT00405158 | N/A | Jan 1, 2002 | Karlstad University |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (26)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cubist | For profit | 2 | 2 | 2 | 2007 |
| German Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2013 |
| GlaxoSmithKline | For profit | 1 | 1 | 1 | 2005 |
| Health Research Board, Ireland | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Karlstad University | Academic/Hospital | 1 | 1 | 1 | 2002 |
| Katholieke Universiteit Leuven | Academic/Hospital | 1 | 1 | 1 | 2006 |
| Mater Misericordiae University Hospital | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Merck | For profit | 1 | 0 | 1 | 2015 |
| Mercy University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Moorgreen Hospital, Southampton | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Murdoch University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| National University of Ireland | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Public Health England | Government | 1 | 0 | 1 | 2013 |
| Royal College of Surgeons, Ireland | Academic/Hospital | 1 | 1 | 1 | 2016 |
| SignaTope GmbH, Germany | For profit | 1 | 0 | 1 | 2021 |
| University of Amsterdam | Academic/Hospital | 1 | 1 | 1 | 2014 |
| University of Baghdad | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Basel | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of Bristol | Academic/Hospital | 1 | 1 | 1 | 2013 |
| University of Duesseldorf | Academic/Hospital | 1 | 1 | 1 | 2013 |
26 organizations
Page 1 / 2